- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06902480
Deieri -kolin biotilgjengelighet
Evaluering av kolinens biotilgjengelighet og metabolisme fra en ny meieriingrediens for kvinner etter menopausale
The goal of this clinical trial is to find out if dairy is a good source of choline compared to eggs. The main questions it aims to answer are:
- How the body uses choline; and,
- What effect WPPC has on choline metabolism.
Researchers will compare Whey Protein Phospholipid Concentrate (WPPC) to whole egg powder to see if WPPC is as effective as eggs.
Participants will drink a chocolate-flavored smoothie mixed with either WPPC or whole egg powder.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This study is intended to evaluate the bioavailability and metabolism of choline in WPPC compared to the most commonly -used food for bioavailable choline, whole egg. The intent of the evaluation is to improve the knowledge of how WPPC contributes to the nutritional needs and health of postmenopausal women.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Kevin Shih
- Telefonnummer: 919-338-9453
- E-post: sshih22@wisc.edu
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53705
- Rekruttering
- University of Wisconsin - Madison
-
Hovedetterforsker:
- Bradley Bolling, PhD
-
Ta kontakt med:
- Kevin Shih
- E-post: sshih22@wisc.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Ages between 51 and 70
- Is currently post-menopausal (Post-menopausal is a term used to describe the time in a woman's life after she has gone through menopause. This usually happens between the ages of 45 and 55. Menopause is when a woman's menstrual periods stop permanently (at least 12 months))
- Not allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds.)
- Had stable body weight (± 5%) for the past 6 months
- Free from cancer
- Did not have weight loss surgery, colon surgery
- Do not have chronic kidney diseases
- Do not have malabsorption towards fat and dairy products
- Willing to complete health surveys
- Willing to complete two 4-day food diaries
- Willing to consume the intervention smoothies
- Willing to provide blood, urine, fecal samples at baseline and after 10 days of intervention
Exclusion Criteria:
- On weight loss/weight gain diets
- Diagnosed with fat malabsorption
- Undergoing weight loss surgery
- Diagnosed with chronic kidney diseases
- Allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, chocolate, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds, banana, strawberry, raspberry, blackberry, blueberry.)
- Regularly using antibiotics or probiotics or prebiotics
- Regularly using weight-loss drugs (GLP-1, Orlistat, Cetilistat, etc.)
- Regularly using laxatives
- Unable to avoid strenuous exercise during the study (>4 h vigorous exercise per day)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Whey Protein Phospholipid Concentrate (WPPC)
Participants will drink a chocolate-flavored smoothie with WPPC added |
A chocolate-flavored smoothie with WPPC added |
|
Eksperimentell: Pasteurized whole egg powder
Participants will drink a chocolate-flavored smoothie with egg powder added |
A chocolate-flavored smoothie with whole egg powder added |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in circulating choline
Tidsramme: Baseline to 10 days
|
Circulating choline will be measured by UHPLC-HRMS/MS |
Baseline to 10 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in co-factors in circulating choline
Tidsramme: Baseline to 10 days
|
Co-factors in the circulation will be measured by ultrahigh performance liquid chromatography coupled with high resolution tandem mass spectrometry (UHPLC-HRMS/MS). |
Baseline to 10 days
|
|
Change in high-sensitivity C-reactive protein (hs-CRP)
Tidsramme: Baseline to 10 days
|
Safety biomarker Hs-CRP will be measured using immunoturbidimetry. |
Baseline to 10 days
|
|
Change in circulating choline metabolites
Tidsramme: Baseline to 10 days
|
Metabolites will be measured by UHPLC-HRMS/MS. |
Baseline to 10 days
|
|
Change in 8-hydroxydeoxyguanosine
Tidsramme: Baseline to 10 days
|
The safety biomarker 8-hydroxydeoxyguanosine (8-OHDG) will be measured using enzyme-linked immunosorbent assay (ELISA). |
Baseline to 10 days
|
|
Change in aspartate transaminase
Tidsramme: Baseline to 10 days
|
Aspartate transaminase (AST) will be measured using kinetic methods. |
Baseline to 10 days
|
|
Change in alanine transaminase (ALT)
Tidsramme: Baseline to 10 days
|
Alanine transaminase will be measured using kinetic methods. |
Baseline to 10 days
|
|
Change in creatinine
Tidsramme: Baseline to 10 days
|
Creatinine will be measured using kinetic methods |
Baseline to 10 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Bradley Bolling, PhD, University of Wisconsin, Madison
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2024-1661
- A074000 (Annen identifikator: UW Madison)
- CALS/FOOD SCIENCE (Annen identifikator: UW Madison)
- Protocol Version 4/24/2026 (Annen identifikator: UW Madison)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The research team will share the individual participant data collected during the trial after deidentification. Deidentified data will be stored and shared with DryAd and in accordance with all applicable regulations.
IPD-delingstidsramme
Anticipated data availability will be immediately following publication. No end date.
Tilgangskriterier for IPD-deling
Data will be shared with DryAd. The data generated in this study will be housed in DryAd.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .